300
Participants
Start Date
June 20, 2019
Primary Completion Date
December 1, 2019
Study Completion Date
December 1, 2019
Liraglutide 6 MG/ML Pen Injector
Patients in each arm will receive either CinnaGen-liraglutide or Victoza®. Both products will be provided as pen-injector.
Metformin
Patients who were receiving metformin with maximum tolerable dose prior to study will continue to receive it during the study.
Sulfonylurea/non-sulfonylurea insulin secretagogues
Patients who were receiving Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose prior to study will continue to receive it during the study.
Lead Sponsor
Cinnagen
INDUSTRY